Vaccines are a key part of a long-term strategy to bring SARS-CoV-2 under control. It is essential to rollout vaccination rapidly to protect as many people as possible and to lower the opportunities for the virus to evolve further. Any vaccine must be authorised by the European Medicines Agency (EMA).

The European Commission has secured up to 4.4 billion doses of COVID-19 vaccines so far and negotiations are underway for additional doses. However, countries are facing different challenges around the disinformation or vaccine acceptance. The European Parliament is trying to keep an eye on the purchase and safety of these vaccines. During June plenary the EP adopted a resolution calling for COVID-19 vaccine patent waiver. Parliament proposed negotiations start for a temporary waiver of the WTO TRIPS Agreement on patents to improve global access to affordable COVID-19-related medical products and to address global production constraints and supply shortages. The EP approved also the Digital Green Certificate to facilitate the safe free movement of citizens within the EU during the pandemic.

Renginio data	2021-09-16
Reference:	20210916EP118668EENG0070
Nuoroda:	EP-118668E
Fotografas:	Genevieve ENGEL
Copyright:	© European Union 2021 - Source : EP
Naudojimo sąlygos:	Identification of origin mandatory

EP Plenary session - EU transparency in the development, purchase and distribution of COVID-19 vaccines

Išsami informacija

Tags